Xiaojiaoyang Li1, Runping Liu1, Zhiming Huang2, Emily C Gurley1,3, Xuan Wang1, Juan Wang4, Hongliang He4, Hu Yang4, Guanhua Lai5, Luyong Zhang6,7, Jasmohan S Bajaj3, Melanie White3, William M Pandak3, Phillip B Hylemon1, Huiping Zhou1,2. 1. Department of Microbiology and Immunology and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA. 2. Department of Gastroenterology, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China. 3. Division of Gastroenterology, Hepatology and Nutrition and McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA. 4. Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA. 5. Department of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA. 6. Guangdong Pharmaceutical University, Guangzhou, China. 7. China Pharmaceutical University, Nanjing, Jiangsu, China.
Abstract
Cholestatic liver injury is an important clinical problem with limited understanding of disease pathologies. Exosomes are small extracellular vesicles released by a variety of cells, including cholangiocytes. Exosome-mediated cell-cell communication can modulate various cellular functions by transferring a variety of intracellular components to target cells. Our recent studies indicate that the long noncoding RNA (lncRNA), H19, is mainly expressed in cholangiocytes, and its aberrant expression is associated with significant down-regulation of small heterodimer partner (SHP) in hepatocytes and cholestatic liver injury in multidrug resistance 2 knockout (Mdr2-/- ) mice. However, how cholangiocyte-derived H19 suppresses SHP in hepatocytes remains unknown. Here, we report that cholangiocyte-derived exosomes mediate transfer of H19 into hepatocytes and promote cholestatic injury. Hepatic H19 level is correlated with severity of cholestatic injury in both fibrotic mouse models, including Mdr2-/- mice, a well-characterized model of primary sclerosing cholangitis (PSC), or CCl4 -induced cholestatic liver injury mouse models, and human PSC patients. Moreover, serum exosomal-H19 level is gradually up-regulated during disease progression in Mdr2-/- mice and patients with cirrhosis. H19-carrying exosomes from the primary cholangiocytes of wild-type (WT) mice suppress SHP expression in hepatocytes, but not the exosomes from the cholangiocytes of H19-/- mice. Furthermore, overexpression of H19 significantly suppressed SHP expression at both transcriptional and posttranscriptional levels. Importantly, transplant of H19-carrying serum exosomes of old fibrotic Mdr2-/- mice significantly promoted liver fibrosis (LF) in young Mdr2-/- mice. CONCLUSION: Cholangiocyte-derived exosomal-H19 plays a critical role in cholestatic liver injury. Serum exosomal H19 represents a noninvasive biomarker and potential therapeutic target for cholestatic diseases. (Hepatology 2018).
Cholestatic liver injury is an important clinical problem with limited understanding of disease pathologies. Exosomes are small extracellular vesicles released by a variety of cells, including cholangiocytes. Exosome-mediated cell-cell communication can modulate various cellular functions by transferring a variety of intracellular components to target cells. Our recent studies indicate that the long noncoding RNA (lncRNA), H19, is mainly expressed in cholangiocytes, and its aberrant expression is associated with significant down-regulation of small heterodimer partner (SHP) in hepatocytes and cholestatic liver injury in multidrug resistance 2 knockout (Mdr2-/- ) mice. However, how cholangiocyte-derived H19 suppresses SHP in hepatocytes remains unknown. Here, we report that cholangiocyte-derived exosomes mediate transfer of H19 into hepatocytes and promote cholestatic injury. Hepatic H19 level is correlated with severity of cholestatic injury in both fibrotic mouse models, including Mdr2-/- mice, a well-characterized model of primary sclerosing cholangitis (PSC), or CCl4 -induced cholestatic liver injurymouse models, and humanPSCpatients. Moreover, serum exosomal-H19 level is gradually up-regulated during disease progression in Mdr2-/- mice and patients with cirrhosis. H19-carrying exosomes from the primary cholangiocytes of wild-type (WT) mice suppress SHP expression in hepatocytes, but not the exosomes from the cholangiocytes of H19-/- mice. Furthermore, overexpression of H19 significantly suppressed SHP expression at both transcriptional and posttranscriptional levels. Importantly, transplant of H19-carrying serum exosomes of old fibrotic Mdr2-/- mice significantly promoted liver fibrosis (LF) in young Mdr2-/- mice. CONCLUSION: Cholangiocyte-derived exosomal-H19 plays a critical role in cholestatic liver injury. Serum exosomal H19 represents a noninvasive biomarker and potential therapeutic target for cholestatic diseases. (Hepatology 2018).
Authors: Hiroyuki Nojima; Christopher M Freeman; Rebecca M Schuster; Lukasz Japtok; Burkhard Kleuser; Michael J Edwards; Erich Gulbins; Alex B Lentsch Journal: J Hepatol Date: 2015-08-05 Impact factor: 25.083
Authors: Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall Journal: Nat Cell Biol Date: 2007-05-07 Impact factor: 28.824
Authors: Anne Gabory; Marie-Anne Ripoche; Anne Le Digarcher; Françoise Watrin; Ahmed Ziyyat; Thierry Forné; Hélène Jammes; Justin F X Ainscough; M Azim Surani; Laurent Journot; Luisa Dandolo Journal: Development Date: 2009-09-17 Impact factor: 6.868
Authors: Dae Joong Kang; Naga S Betrapally; Siddhartha A Ghosh; R Balfour Sartor; Phillip B Hylemon; Patrick M Gillevet; Arun J Sanyal; Douglas M Heuman; Daniel Carl; Huiping Zhou; Runping Liu; Xiang Wang; Jing Yang; Chunhua Jiao; Jeremy Herzog; H Robert Lippman; Masoumeh Sikaroodi; Robert R Brown; Jasmohan S Bajaj Journal: Hepatology Date: 2016-07-29 Impact factor: 17.425
Authors: Mohammed S Al Suraih; Christy E Trussoni; Patrick L Splinter; Nicholas F LaRusso; Steven P O'Hara Journal: Liver Int Date: 2020-07-07 Impact factor: 5.828
Authors: Amaia Navarro-Corcuera; Tejasav S Sehrawat; Nidhi Jalan-Sakrikar; Hunter R Gibbons; Nicholas E Pirius; Shalil Khanal; Feda H Hamdan; Sayed Obaidullah Aseem; Sheng Cao; Jesus M Banales; Ningling Kang; William A Faubion; Nicholas F LaRusso; Vijay H Shah; Robert C Huebert Journal: J Hepatol Date: 2021-12-23 Impact factor: 25.083